Harnessing Innovation to Forge Value Foundations — Live Report from Dorrapharma at CPHI China 2026

发布时间： 2026-06-18 阅读：36次

分享

【Global Attention Once Again on Shanghai】
On June 16, the 24th CPHI China 2026 grandly opened at Shanghai New International Expo Centre. In Hall W3 – the core API zone – Dorrapharma’s distinctive red branding, symbolizing passion and commitment to the industry, attracted a steady stream of global visitors: long‑term European procurement partners, established Southeast Asian formulation manufacturers, and BD and R&D leaders from top domestic pharmaceutical companies. Brochures were handed out one after another, while in‑depth dialogues unfolded on technological innovation, process routes, delivery timelines, and compliance systems.

【Three Business Platforms – Enabling Industry Development with Robust Capabilities】

Service Platform – Leveraging a mature supply‑demand network of over 3,000 suppliers and 1,000+ clients worldwide, we have built a two‑way empowerment system that combines "China supply chain services + global marketing."

R&D Platform – Demonstrating our capability and product portfolio across three dimensions of chemical pharmaceuticals. From high‑value small‑molecule APIs and advanced intermediates covering anti‑infectives, metabolism, and other therapeutic areas, to oral cyclic peptide APIs and key building blocks, and to non‑biological macromolecular polymers with high technical barriers – Dorrapharma rigorously addresses core technological challenges, maintains strict control over supply chain management and manufacturing compliance, and delivers greater value through products and services to the global pharmaceutical market.

Formulation Platform – Driven by a dual‑engine "MAH + Licensing" model. The Licensing segment precisely selects products already approved in Europe, the U.S., and Japan, with promising competitive dynamics in China and significant clinical value, and achieves local market entry through branded operations.

【Steady Progress for Sustainable Growth】
CPHI China 2026 has now concluded successfully. Hundreds of in‑depth engagements during the show served as a comprehensive review of Dorrapharma’s overall strength. Looking ahead, we are committed to becoming “A global leading APl ecosystem partner driven by innovation.” Through technological innovation, we will lead industrial upgrading; through reliable supply, we will safeguard global health. Together with our industry peers, we aim to build a more resilient pharmaceutical ecosystem in an era of uncertainty.